Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Combined Use of Botulinum Toxin A and Profhilo for Upper Face Rejuvenation: A Randomized Clinical Trial

Saffarian Z., Rahimnia A., Ehsani A., Balighi K., Amirhoushang Ehsani, Razavi Z.

Clinical Trial with a reported sample of 10 on Skin Aging, Facial Rejuvenation, published in Health Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Health Sci Rep (2026)
Reported sample size
10
Source database
Europe PMC
PMID
42063688
PMCID
PMC13125427
DOI
10.1002/hsr2.71973
Citations
1

Abstract (original English)

Background Hyaluronic acid (HA) and Botulinum toxin A (BTX-A) treatments are highly regarded for their effectiveness in facial rejuvenation. Aim To investigate whether adding Profhilo enhances the effects of BTX-A for frontal skin rejuvenation. Method In a prospective clinical trial, 10 subjects were treated by upper face Profhilo plus Botulinum toxin A injection, and 10 age- and sex-matched controls received only Botulinum toxin A injection. Clinical and sonographic improvement were compared 3 months after the last treatment session. Results A total of 20 participants (10 patients in each group), including 8 males (80%) and 2 females (20%) in the case group and 7 males (70%) and 3 females (30%) in the control group, were enrolled in the study. According to Merz scores before and 3 months after treatment, the wrinkles were dramatically reduced in both groups ( p value: p value: 0.633). None of the sonographic variables, including dermis and hypodermis thickness and elasticity, significantly changed after treatment with BTX-A alone ( p values: 0.910 and 0.770, respectively) or with Profhilo injection ( p values: 0.261 and 0.670, respectively). Conclusion We have shown that adding Profhilo to BTX-A injection does not have any short-term clinical or sonographic advantage in frontal area wrinkle reduction. Further prospective studies with a longer follow-up period are warranted to

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research